Odyssey Therapeutics' OD-001 meets primary endpoint in Phase 2a ulcerative colitis trial
ODTX•Odyssey Therapeutics said its oral OD-001 met the primary efficacy endpoint in a Phase 2a trial in moderate-to-severe ulcerative colitis. The open-label study had no concurrent placebo control; the company plans further trials, with topline induction results expected in the second half of 2027.
1. Trial results and next steps
Odyssey Therapeutics presented completed Phase 2a induction results for oral OD-001 at UEG Week on Oct. 20, 2026. The trial met its primary efficacy endpoint, with improvements in symptoms and inflammatory markers; OD-001 was generally well tolerated, with no serious adverse events or treatment-related discontinuations during induction. The open-label study had no concurrent placebo control. Randomized Phase 2b monotherapy and Phase 2a vedolizumab combination trials are planned, with topline induction results expected in the second half of 2027.
